158 related articles for article (PubMed ID: 31597506)
21. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
22. Everolimus in pregnancy: Case report and literature review.
Yamamura M; Kojima T; Koyama M; Sazawa A; Yamada T; Minakami H
J Obstet Gynaecol Res; 2017 Aug; 43(8):1350-1352. PubMed ID: 28557245
[TBL] [Abstract][Full Text] [Related]
23. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
Alsidawi S; Kasi PM
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus and temsirolimus for epithelioid angiomyolipoma.
Wolff N; Kabbani W; Bradley T; Raj G; Watumull L; Brugarolas J
J Clin Oncol; 2010 Feb; 28(5):e65-8. PubMed ID: 20048172
[No Abstract] [Full Text] [Related]
25. TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study.
Jacob LA; Shafi G
Indian J Cancer; 2019; 56(3):274-275. PubMed ID: 31389395
[TBL] [Abstract][Full Text] [Related]
26. ♣Evaluation of clinicopathological profiles and development of a risk model in renal epithelioid angiomyolipoma patients: a large-scale retrospective cohort study.
Anwaier A; Xu WH; Tian X; Ding T; Su JQ; Wang Y; Qu YY; Zhang HL; Ye DW
BMC Urol; 2022 Sep; 22(1):148. PubMed ID: 36096809
[TBL] [Abstract][Full Text] [Related]
27. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma.
Song X; Said Q; Tran O; Krueger DA; Bissler J
Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347
[TBL] [Abstract][Full Text] [Related]
28. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.
Hatano T; Egawa S
Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574
[TBL] [Abstract][Full Text] [Related]
29. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome.
Martignoni G; Bonetti F; Pea M; Tardanico R; Brunelli M; Eble JN
Am J Surg Pathol; 2002 Feb; 26(2):198-205. PubMed ID: 11812941
[TBL] [Abstract][Full Text] [Related]
30. Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report.
Kohno J; Matsui Y; Yamasaki T; Shibasaki N; Kamba T; Yoshimura K; Sumiyoshi S; Mikami Y; Ogawa O
Int J Urol; 2013 Sep; 20(9):938-41. PubMed ID: 23347205
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.
Budde K; Zonnenberg BA; Frost M; Cheung W; Urva S; Brechenmacher T; Stein K; Chen D; Kingswood JC; Bissler JJ
Br J Clin Pharmacol; 2016 May; 81(5):958-70. PubMed ID: 26580489
[TBL] [Abstract][Full Text] [Related]
32. Angiomyolipoma have common mutations in TSC2 but no other common genetic events.
Qin W; Bajaj V; Malinowska I; Lu X; MacConaill L; Wu CL; Kwiatkowski DJ
PLoS One; 2011; 6(9):e24919. PubMed ID: 21949787
[TBL] [Abstract][Full Text] [Related]
33. Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis.
Sato K; Ueda Y; Tachibana H; Miyazawa K; Chikazawa I; Kaji S; Nojima T; Katsuda S
Pathol Res Pract; 2008; 204(10):771-7. PubMed ID: 18547741
[TBL] [Abstract][Full Text] [Related]
34. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2.
Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J
Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159
[TBL] [Abstract][Full Text] [Related]
35. Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
Yang J; Samsel PA; Narov K; Jones A; Gallacher D; Gallacher J; Sampson JR; Shen MH
Neoplasia; 2017 Feb; 19(2):112-120. PubMed ID: 28092822
[TBL] [Abstract][Full Text] [Related]
36. Dia-gnostic Challenges and Extraordinary Treatment Response in Rare Malignant PEComa Tumor of the Kidney.
Huľová S; Sycova-Mila Z; Macák D; Janega P; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2018; 31(6):448-452. PubMed ID: 30545225
[TBL] [Abstract][Full Text] [Related]
37. Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.
Geynisman DM; Kadow BT; Shuch BM; Boorjian SA; Matin SF; Rampersaud E; Milestone BN; Plimack ER; Zibelman MR; Kutikov A; Smaldone MC; Chen DY; Viterbo R; Joshi S; Greenberg RE; Malizzia L; McGowan T; Ross EA; Uzzo RG
J Urol; 2020 Sep; 204(3):531-537. PubMed ID: 32250730
[TBL] [Abstract][Full Text] [Related]
38. Sequential everolimus for angiomyolipoma associated with tuberous sclerosis complex: a prospective cohort study.
Gu L; Peng C; Zhang F; Fang C; Guo G
Orphanet J Rare Dis; 2021 Jun; 16(1):277. PubMed ID: 34127034
[TBL] [Abstract][Full Text] [Related]
39. Molecular Characterization of Malignant Renal Epithelioid Angiomyolipoma: A Review of Two Cases.
Rammal R; Korentzelos D; Skaugen JM; Quiroga-Garza GM
Am J Clin Pathol; 2023 Mar; 159(3):211-220. PubMed ID: 36661215
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic effect of everolimus on small renal angiomyolipoma in cases of tuberous sclerosis complex-related epilepsy and subependymal giant cell astrocytoma.
Hatano T; Yuri Y
Asian J Surg; 2023 Mar; 46(3):1236-1237. PubMed ID: 36031512
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
